A double‑blind, placebo‑controlled Homoeopathic Pathogenetic Trial of Nanocurcumin 6X

Abstract

Background: A double‑blind, randomized, placebo‑controlled Homoeopathic Pathogenetic Trial (HPT) of Nanocurcumin was conducted using the accepted guidelines, Ethical Committee approval, and scientific documentation. The standardized potentization method was adopted to enhance the quality of the pathogenetic trial. Various statistical calculations were used for evaluation of the symptoms. Aim: The aim of the study was to conduct an HPT of Nanocurcumin 6X, a nanosubstance in dilution. Materials and Methods: The drug Nanocurcumin 6X was proved through double‑blind, placebo‑controlled method. The trial was done in 6X potency on 30 healthy provers who were screened by their pretrial medical examinations and routine laboratory investigations. Of 30 provers, 7 were on placebo and 23 were on drug. Medicine was prepared according to the principles of trituration given in Homoeopathic Pharmacopeia of India. The signs and symptoms generated during the trial period were noted by the provers and decoded and compiled afterwards. Results: Of 23 provers who were on verum 17 provers manifested symptoms and out of 7 provers who were on placebo 2 manifested symptoms. Conclusion: The drug pathogenesis evolved indicates its therapeutic use in sinusitis, migraine, dyspepsia, constipation, diarrhoea, dysmenorrhoea, pharyngitis, bronchitis, etc.